Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents.

Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev. 2017 Jun 06;: Authors: Böttcher K, Pinzani M Abstract Liver fibrosis and cirrhosis resulting from long-standing liver damage represents a major health care burden worldwide. To date, there is no anti-fibrogenic agent available, making liver transplantation the only curative treatment for decompensated cirrhotic liver disease. Liver fibrosis can result from different underlying chronic liver disease, such as chronic viral infection, excessive alcohol consumption, fatty liver disease or autoimmune liver diseases. It is becoming increasingly recognised that as a result from different pathogenic mechanisms liver fibrosis must be considered as many different diseases for which individual treatment strategies need to be developed. Moreover, the pathogenic changes of both liver architecture and vascularisation in cirrhotic livers, as well as the lack of "true-to-life" in vitro models have impeded the development of an effective anti-fibrogenic drug. Thus, in order to identify an efficient anti-fibrogenic compound, novel in-vitro models mimicking the interplay between pro-fibrogenic cell populations, immune cells and, importantly, the extracellular matrix need to be developed. PMID: 28600202 [PubMed - as supplied by publisher]
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Tags: Adv Drug Deliv Rev Source Type: research

Related Links:

Abstract Systemic lupus erythematosus (SLE), a multisystem autoimmune inflammatory disease, may involve any organs, including the liver. Liver involvement in SLE is not part of the American College of Rheumatology criteria and is relatively rare. Liver disease is usually mild, manifesting as subtle elevation of liver enzymes. Jaundice and hepatomegaly can be seen in some patients; advanced liver disease with cirrhosis is extremely rare. Precise pathology remains obscure. SLE may cause non-specific changes, including hepatocellular, cholestatic, or vascular changes. Alcohol, drugs, viral infections, metabolic disor...
Source: Scandinavian Journal of Rheumatology - Category: Rheumatology Authors: Tags: Scand J Rheumatol Source Type: research
ConclusionCOVID-19 is associated with poor outcomes in patients with cirrhosis, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
In conclusion, emodin has a good effect on liver protection, but further experimental data are needed to verify it. PMID: 32553811 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol. 2020 May 28;26(20):2559-2569 Authors: Zhou QH, Wu FT, Pang LT, Zhang TB, Chen Z Abstract γδT cells are unconventional T lymphocytes that bridge innate and adaptive immunity. Based on the composition of T cell receptor and the cytokines produced, γδT cells can be divided into diverse subsets that may be present at different locations, including the liver, epithelial layer of the gut, the dermis and so on. Many of these cells perform specific functions in liver ...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
Clinical Liver Disease, Volume 15, Issue 5, Page 195-199, May 2020.
Source: Clinical Liver Disease - Category: Gastroenterology Authors: Tags: Review Source Type: research
Chronic liver diseases (CLD) are a worldwide clinical problem, as they are related to high morbidity and mortality. The principal causes include viral, alcoholism, cholestatic, autoimmune and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These CLD can evolve into cirrhosis and hepatocellular carcinoma (HCC) [1]. Patients with CLD showed significant health problems like ascites, spontaneous bacterial peritonitis, hepatic encephalopathy and persistent variceal bleeding concomitant with a decrease in health-related quality of life [1-3].
Source: Prostaglandins, Leukotrienes and Essential Fatty Acids - Category: Biomedical Science Authors: Source Type: research
ndez-Cano VH, Macías-Rodríguez RU Abstract Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in these patients ranges from abnormalities in liver function tests (LFTs) to fulminant hepatic failure. Usually, abnormalities in LFTs are only mild and transient, have a hepatocellular pattern and are not related to SLE but rather are mostly drug related. The most freq...
Source: Lupus - Category: Rheumatology Authors: Tags: Lupus Source Type: research
AbstractObjectivesTo evaluate whether the liver and spleen volumetric indices, measured on portal venous phase CT images, could be used to assess liver fibrosis severity in chronic liver disease.MethodsFrom 2007 to 2017, 558 patients (mean age 48.7  ± 13.1 years; 284 men and 274 women) with chronic liver disease (n = 513) or healthy liver (n = 45) were retrospectively enrolled. The liver volume (sVolL) and spleen volume (sVolS), normalized to body surface area and liver-to-spleen volume ratio (VolL/VolS), were measured on CT images using a deep learning algorithm. The c...
Source: European Radiology - Category: Radiology Source Type: research
Liver diseases, including liver cancer, cirrhosis, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), impose a heavy disease burden worldwide [1,2]. Liver cancer and cirrhosis may derive from any chronic liver disease, such as hepatitis B/C virus (HBV/HCV) infections, alcoholic liver disease, NAFLD, haemochromatosis, and autoimmune hepatitis [3]. Over the last four decades, the prevalence of overweight has increased over fourfold in children, and there has been a great relative increase in obesity prevalence with no signs of slowing [4].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
CONCLUSION: Thrombocytopenia is an infrequent event in NAFLD patients without cirrhosis and is related with male sex and higher hemoglobin levels. PMID: 31575467 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
More News: Alcoholism | Autoimmune Disease | Cirrhosis | Drugs & Pharmacology | Fatty Liver Disease (FLD) | Health Management | Liver | Liver Disease | Liver Transplant | Transplants | Urology & Nephrology